Related Experiment Video
Updated: Jun 4, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Dual-template epitope imprinted nanoparticles for anti-glycolytic tumor-targeted treatment
Da-Wei Wang1, Xing-Hui Ren1, Yao-Jia Ma1
1State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Center for Analytical Sciences, College of Chemistry, Nankai University, Tianjin 300071, China.
Abstract:
Glycolysis provides tumors with abundant nutrients through glucose (Glu) metabolism. As a therapeutic target, precise targeting and effective inhibition of the glycolysis process remains a major challenge in anti-metabolic therapy. In this study, a novel dual-template molecularly imprinted polymer (D-MIP), capable of specifically recognizing glucose transporter member 1 (GLUT1) and hexokinase-2 (HK2) was prepared for anti-glycolytic tumor therapy. The imprinting factors of D-MIP for the recognition of the template molecules, the GLUT1 epitope and the HK2 epitope, were 2.1 and 2.5, respectively, enabling specific recognition of the entire target protein. Targeting GLUT1 with D-MIP could impede its Glu uptake, while simultaneously inhibiting the activity of cytoplasmic HK2, thereby reducing the metabolic rate of Glu. Cell experiments demonstrated that inhibition of HK2 resulted in downregulation of the downstream, products glucose-6-phosphate (6PG) and lactate (LA). In vitro and in vivo experimental results indicated that D-MIP exhibited significant targeting and inhibitory effects on GLUT1 and HK2, respectively, which suppressed tumor glycolysis and induced apoptosis in MCF-7 cells. Furthermore, mouse tumor models and hematoxylin-eosin (H&E) staining confirmed the excellent anti-tumor efficacy and favorable biocompatibility of D-MIP. This work represents the first design and development of a dual-template imprinted polymer targeting key transport channels and metabolic enzymes involved in glycolysis, advancing the research and application of anti-glycolytic tumor therapy.
Insights
A novel dual-template molecularly imprinted polymer (D-MIP) specifically targets glucose transporter member 1 (GLUT1) and hexokinase-2 (HK2). This D-MIP effectively suppresses tumor glycolysis and induces apoptosis, showing promising anti-tumor efficacy.
Area of Science:
- Biomaterials Science
- Cancer Therapy
- Metabolic Engineering
Background:
- Tumor cells rely on glycolysis for nutrients via glucose metabolism.
- Targeting glycolysis is challenging in anti-metabolic cancer therapy.
- Specific inhibition of glucose uptake and metabolism is crucial.
Purpose of the Study:
- To develop a novel dual-template molecularly imprinted polymer (D-MIP).
- To enable specific recognition and inhibition of glucose transporter member 1 (GLUT1) and hexokinase-2 (HK2).
- To evaluate D-MIP's efficacy in anti-glycolytic tumor therapy.
Main Methods:
- Preparation of a dual-template molecularly imprinted polymer (D-MIP).
- Assessment of D-MIP's specific recognition of GLUT1 and HK2 epitopes.
- In vitro and in vivo experiments using cell lines (MCF-7) and mouse tumor models.
- Evaluation of anti-tumor efficacy and biocompatibility through various assays and H&E staining.
Main Results:
- D-MIP demonstrated specific recognition of GLUT1 and HK2 with imprinting factors of 2.1 and 2.5.
- D-MIP effectively inhibited glucose uptake by targeting GLUT1 and suppressed HK2 activity.
- Inhibition of HK2 led to reduced downstream products like glucose-6-phosphate and lactate.
- Significant suppression of tumor glycolysis, induction of apoptosis in MCF-7 cells, and excellent anti-tumor efficacy in vivo were observed.
- Favorable biocompatibility of D-MIP was confirmed.
Conclusions:
- D-MIP is the first dual-template imprinted polymer designed to target key glycolysis players (GLUT1 and HK2).
- This approach effectively impedes tumor glycolysis and induces cancer cell apoptosis.
- D-MIP shows significant anti-tumor efficacy and good biocompatibility, advancing anti-glycolytic therapy research.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy